MediPharm Labs Faces Insolvency Risk as Q1 Losses Hit $3.3M, Warns Apollo Capital

MediPharm is Dangerously Low On Cash and is On Track to Run Out of Money by November Unless Wholesale Change Occurs

MediPharm Lost Over $3.3 Million in Q1 2025 While Management Offered No Clear Plan to Achieve Profitability or Commitment to Reduce Waste or Excessive Spending

Apollo Capital Warns Shareholders Not to Be Misled by Management’s Rosy Outlook: MediPharm has Reported 21 Consecutive Quarters of Losses, Yet CEO Pidduck Touted Adjusted EBITDA, a Cherry-Picked Figure That is Meaningless

Absent Significant Board Change, MediPharm Stock is On Its Way to Being Worthless! Apollo Capital’s Nominees Bring the Turnaround Experience and Financial Discipline Required to Stop the Bleeding, Restore Fiscal Integrity, and Deliver Performance…